FindTrial
Sign In

Metabolically Armed CD19 CAR-T cells

DRUG7 trials

Sponsors

Anhui Provincial Hospital, He Huang, The Children's Hospital of Zhejiang University School of Medicine, Zhejiang University

Conditions

Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaNon-hodgkin LymphomaNon-hodgkin Lymphoma,B CellSystemic Lupus Erythematosus

Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT05715606
Anhui Provincial HospitalDiffuse Large B-cell Lymphoma
Start: 2023-02-10End: 2025-05-15Target: 18Updated: 2023-07-05
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
NCT05747157
Anhui Provincial HospitalB-cell Acute Lymphoblastic Leukemia
Start: 2023-02-15End: 2025-05-15Target: 18Updated: 2023-11-21
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
RecruitingNCT06120166
He HuangDiffuse Large B-cell Lymphoma
Start: 2023-11-16End: 2026-04-05Target: 18Updated: 2025-09-19
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
RecruitingNCT06277011
Anhui Provincial HospitalAcute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Start: 2023-02-10End: 2025-05-15Target: 18Updated: 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
RecruitingNCT06393335
The Children's Hospital of Zhejiang University School of MedicineAcute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Start: 2024-05-15End: 2026-03-15Target: 36Updated: 2024-05-01
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
RecruitingNCT06711146
Zhejiang UniversitySystemic Lupus Erythematosus
Start: 2024-12-24End: 2027-04-05Target: 36Updated: 2026-08-24
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
RecruitingNCT06716164
Zhejiang UniversityNon-hodgkin Lymphoma,B Cell
Start: 2024-12-01End: 2027-04-05Target: 36Updated: 2024-12-04

Related Papers

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
2026-07-23
Phase 1 study of META 10-19, an IL-10-expressing, anti-CD19 CAR T cell product in patients with high-risk DLBCL.
Journal of Clinical Oncology2026-05-27
Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis
Blood2025-11-03
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.
2025-10-16
IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
Blood2024-11-058 citations
1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust <i>in vivo</i> Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
Blood2024-11-05
Abstract LB236: Metabolically armed CD19 CAR-T cells for safe and effective treatment of relapsed or refractory CD19+ B cell hematological malignancies at extremely low doses
Cancer Research2024-04-051 citations